5398722026-01-012026-03-315398722026-03-315398722025-03-315398722025-04-012026-03-315398722026-01-012026-03-31in-capmkt:OtherExpenses1Member5398722026-01-012026-03-31in-capmkt:OtherExpenses2Member5398722026-01-012026-03-31in-capmkt:OtherExpenses3Member5398722026-01-012026-03-31in-capmkt:OtherExpenses4Member5398722026-01-012026-03-31in-capmkt:OtherExpenses5Member5398722026-01-012026-03-31in-capmkt:OtherExpenses6Member5398722026-01-012026-03-31in-capmkt:OtherExpenses7Member5398722026-01-012026-03-31in-capmkt:OtherExpenses8Member5398722026-01-012026-03-31in-capmkt:OtherExpenses9Member5398722026-01-012026-03-31in-capmkt:OtherExpenses10Member5398722025-04-012026-03-31in-capmkt:OtherExpenses1Member5398722025-04-012026-03-31in-capmkt:OtherExpenses2Member5398722025-04-012026-03-31in-capmkt:OtherExpenses3Member5398722025-04-012026-03-31in-capmkt:OtherExpenses4Member5398722025-04-012026-03-31in-capmkt:OtherExpenses5Member5398722025-04-012026-03-31in-capmkt:OtherExpenses6Member5398722025-04-012026-03-31in-capmkt:OtherExpenses7Member5398722025-04-012026-03-31in-capmkt:OtherExpenses8Member5398722025-04-012026-03-31in-capmkt:OtherExpenses9Member5398722025-04-012026-03-31in-capmkt:OtherExpenses10Member5398722026-03-31OtherNoncurrentFinancialAssetsDomain15398722026-03-31OtherNoncurrentFinancialAssetsDomain25398722026-03-31OtherNoncurrentAssetsDomain15398722026-03-31OtherCurrentFinancialAssetsDomain15398722026-03-31OtherCurrentFinancialAssetsDomain25398722026-03-31OtherCurrentFinancialAssetsDomain35398722026-03-31OtherCurrentFinancialAssetsDomain45398722026-03-31OtherCurrentFinancialAssetsDomain55398722026-03-31OtherCurrentAssetsDomain15398722026-03-31OtherCurrentAssetsDomain25398722026-03-31OtherCurrentAssetsDomain35398722026-03-31OtherCurrentAssetsDomain45398722026-03-31OtherCurrentAssetsDomain55398722026-03-31OtherNoncurrentFinancialLiabilitiesDomain15398722026-03-31OtherCurrentFinancialLiabilitiesDomain15398722026-03-31OtherCurrentFinancialLiabilitiesDomain25398722026-03-31OtherCurrentFinancialLiabilitiesDomain35398722026-03-31OtherCurrentLiabilitiesDomain15398722026-03-31OtherCurrentLiabilitiesDomain25398722026-03-31OtherCurrentLiabilitiesDomain35398722026-01-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15398722025-04-012026-03-31ItemsThatWillNotBeReclassifiedToProfitAndLoss15398722026-01-012026-03-31RelatedPartyTransactionDomain15398722025-12-31RelatedPartyTransactionDomain15398722026-03-31RelatedPartyTransactionDomain15398722026-01-012026-03-31RelatedPartyTransactionDomain25398722025-12-31RelatedPartyTransactionDomain25398722026-03-31RelatedPartyTransactionDomain25398722026-01-012026-03-31RelatedPartyTransactionDomain35398722025-12-31RelatedPartyTransactionDomain35398722026-03-31RelatedPartyTransactionDomain35398722026-01-012026-03-31RelatedPartyTransactionDomain45398722025-12-31RelatedPartyTransactionDomain45398722026-03-31RelatedPartyTransactionDomain45398722026-01-012026-03-31RelatedPartyTransactionDomain55398722025-12-31RelatedPartyTransactionDomain55398722026-03-31RelatedPartyTransactionDomain55398722026-01-012026-03-31RelatedPartyTransactionDomain65398722025-12-31RelatedPartyTransactionDomain65398722026-03-31RelatedPartyTransactionDomain65398722026-01-012026-03-31RelatedPartyTransactionDomain75398722025-12-31RelatedPartyTransactionDomain75398722026-03-31RelatedPartyTransactionDomain75398722026-01-012026-03-31RelatedPartyTransactionDomain85398722025-12-31RelatedPartyTransactionDomain85398722026-03-31RelatedPartyTransactionDomain85398722026-01-012026-03-31RelatedPartyTransactionDomain95398722025-12-31RelatedPartyTransactionDomain95398722026-03-31RelatedPartyTransactionDomain95398722026-01-012026-03-31RelatedPartyTransactionDomain105398722025-12-31RelatedPartyTransactionDomain105398722026-03-31RelatedPartyTransactionDomain105398722026-01-012026-03-31AuditorDomain15398722026-03-31Statement15398722026-01-012026-03-31Statement15398722026-03-31StatementDynamic1I1Statement15398722026-03-31StatementDynamic1I2Statement15398722026-03-31StatementDynamic1I3Statement1iso4217:INRxbrli:pureiso4217:INRxbrli:shares539872BAJAJHCARENOTLISTEDINE411U01027BAJAJ HEALTHCARE LIMITEDMain BoardEquity2025-04-012026-03-312026-05-082026-05-02INRLakhsQuarterlyFourth quarterSingle segmentPharmaceuticals2026-05-0817:15:002026-05-0818:30:00trueCash Flow IndirectDeclaration of unmodified opiniontruetrueNANAfalsetrue2025-02-11https://www.bajajhealth.com/policies/true1falseDuring the period ended 31.03.2026, there is no default on Loans and Debt Securities.2026-01-012026-03-31AuditedStandalone15305750002956200015601370009210060000-10590100016301100055658000762870003256980001435759000124378000-332466000-2080880000-13960000-139600000-194128000-2301800011360000-343780000-228506000486000-2280200001683130005-6.08-6.07-1.08-1.08-7.16-7.150.441.243.231. The above Financial Results of Bajaj Healthcare Limited the Company have been reviewed by the Audit Committee and subsequently approved by the Board of Directors at their respective meetings held on 08 May 2026. These results have been subjected to limited review by the Statutory auditors who have expressed an unmodified review conclusion. <BR> <BR> 2. The figures for the quarter ended 31 March 2026 and 31 March 2025 are the balancing figures between the audited figures in respect of the full financial year and the unaudited published figures up to nine months of the relevant financial year. <BR> <BR> 3. The Company deals in pharmaceuticals products formulations and active pharmaceutical ingredients components which are interlinked and interdependent. Therefore, the Company has identified only one reportable segment i.e. Pharmaceuticals. <BR> <BR> 4. In the year ended 31 March 2024, the Board of Directors had approved to sale disposal of undertaking unit s on going concern basis, situated at plot no N92, L9 3 T 30, MIDC Tarapur, Taluka Boisar, District Palghar, Maharashtra and vacant industrial land situated at plot no. D 2 CH 42 D 2 CH 43 Dahej industrial area, GIDC, Bharuch, Gujarat which were acquired under SARFAESI ACT, 2022 from Saraswat Bank and plot no. E 62 and E 63 MIDC Tarapur Taluka Boisar, District Palghar, Maharashtra. The approval of shareholders was obtained vide postal ballot. The Company has classified the assets and liabilities in relation to these units as Assets and liabilities held for sale disposal under Ind AS 105 Non current Assets Held for Sale and Discontinued Operations. The results of the operation of these units have been presented separately on the Statement of Profit and Loss as Discontinued Operations. Out of these, one unit situated at plot no. N 92 was sold during the Quarter ended 31 March 2024 and one unit situated at plot no. L 9 3 was sold during the Quarter ended 31 March 2026. The total value of assets classified as held for sale represents lower of carrying value or fair value. <BR> <BR> 5. The Board of Directors at its meeting held on 18 March 2026, considered and approved the allotment of 20,79,409 fully Paid up Equity Shares of the Company of face value of Rs. 5 each the Equity Shares to the Promoter, Promoter Group and Person s belonging to the Non Promoter Public Category, pursuant to the exercise of the option for Conversion of Warrants into Equity Shares at a price of Rs. 338 per Equity Share including a premium of Rs. 333 for each Convertible Warrant. The allotment has been made pursuant to the Special Resolution passed by the shareholders at the Extra Ordinary General Meeting held on 7 August 2024, in accordance with the provisions of the SEBI Issue of Capital and Disclosure Requirements Regulations, 2018. <BR> Earlier, on 19 September 2024, the Company had allotted 39,84,852 equity shares and 20,79,409 convertible warrants, raising an aggregate amount of Rs. 15225.90 lakhs. This amount included 25 percentage of the warrant issue price, aggregating to Rs.1,757.10 lakhs, which was received at the time of allotment of the convertible warrants. The balance 75 percentage i.e. Rs 5,271.30 lakhs of the issue price has now been received upon the allotment of 20,79,409 equity shares pursuant to the exercise of conversion rights attached to the warrants. <BR> The fund raised through allotment of equity shares and convertible warrants under the preferential issue has been utilised for following activities. <BR> <BR> 6. The Company had entered into a Transfer of Technical Know how arrangement with a customer for one of the products manufactured by the Company. The Technical know how was ultimately to be used by a customer in Middle East. Due to ongoing regional instability in Middle East, the customer was not able to meet its committed timeline. Hence, the Company has reversed the income recognised in earlier year amounting to Rs. 3,324.66 lakhs, in the quarter ended 31 March 2026. <BR> <BR> 7. In April 2025, the Company acquired Genrx Pharmaceuticals Private Limited in Liquidation Genrx, on a going concern basis. Genrx is an existing company incorporated under the provisions of the Companies Act, 1956. The acquisition was made for a total consideration of Rs. 1,085 lakhs. <BR> Subsequently, on 3 June 2025, the Company filed an application with the Honble National Company Law Tribunal NCLT, Mumbai, seeking certain reliefs and concessions necessary for the effective implementation of the acquisition and takeover of Genrx as a going concern, which is pending with NCLT as on 31 March 2026. Hence, Genrx has not been considered a subsidiary for consolidation purpose, pending requisite approvals from the NCLT, as control, defined under Ind AS 110 Consolidated Financial Statements is notB established. <BR> 2025-04-012026-03-31AuditedStandalone61103140007133900061816530003061995000010195400062752600022233700027548400012706610005559957000621696000-332466000289230000076126000761260000213104000-511690004274000-554430000157661000609800016375900016831300051683130006.736.72-1.75-1.754.984.970.442.153.8Debt Equity Ratio is 1.24 for FY 2026 and 2.15 for FY 2025 <BR> <BR> ISCR is 3.23 for FY 2026 and 3.80 for FY 2025Brokerage & Commission9233000Consumption of Stores Spares and Maintainence25568000Freight Forwarding & Transport38276000Insurance Expenses5970000Legal & Professional Expenses21944000Material Testing & Inspection Charges3786000Miscellaneous Expenses17347000Power and Fuel103111000Processing & Labour Charges57472000Others42991000Brokerage & Commission44433000Consumption of Stores Spares and Maintainence170476000Freight Forwarding & Transport144402000Insurance Expenses30125000Legal & Professional Expenses82861000Material Testing & Inspection Charges26893000Miscellaneous Expenses40030000Power and Fuel300199000Processing & Labour Charges201371000Others22987100024722480007941400000981800000033000001369620001369950001065010003707400028420500002160096000023385380003723540007519000052267000277067800007600480005690822000699300000092321720001683130005161710000533002300053300230004756570000002988300050554000071785000005773250001858977000654120001087387000115279900016139700031731730001221100010240000003195624000129200000039021490009232172000Fixed deposits with remaining maturity beyond 12 months28462000Amount paid for Investment in Genrx Pharma108500000Income Tax Receivables37074000Advance to Staff4513000Deposits with original maturity of more than 12 months but maturing within 12 months from reporting date10758000Insurance Claim Receivable5347000Advances given for operating expenses - Genrx Pharma10362000Other Receivable21287000Balance with Statutory Authority324420000Deposit With Public Authorities and Others (Refer 10.1)76560000Prepaid assets95595000Capital advances225000000Advance to Suppliers38473000Lease Liabilities29883000Lease Liabilities126391000Employee related liability34948000Other Payables58000Advances Received from Customers424000Advance for sale of fixed assets1350000Statutory Dues Payable10437000222337000-541219000021334500000-2394400000-311800000892280000275484000-15390000000-65141000000000-511690003725910000271359000560589000000-20224000058081300008100000000000028946000433496000000000000000000000311800004637000-47779500000526080000000009615000738100031096000315830002116970000-10640000243298000346316000034631600026038000372354000Items not to be reclassified to profit or loss in subsequent periods649000649000Items not to be reclassified to profit or loss in subsequent periods814900081490001630002051000004860006098000Bajaj Healthcare Limited******Mr. Sajankumar Rameshwarlal Bajaj******Chairman & Managing DirectorRemunerationNA2124800000Bajaj Healthcare Limited******Mr. Anil Champalal Jain******Managing DirectorRemunerationNA1749800000Bajaj Healthcare Limited******Ms. Namrata Sajankumar Bajaj******Whole-Time DirectorRemunerationNA240600000Bajaj Healthcare Limited******Mr. Pakshal Anil Jain******Whole-Time DirectorRemunerationNA241500000Bajaj Healthcare Limited******Mrs. Harshavi Pakshal Jain******Wife of Mr. Pakshal Jain, Whole-Time Director & Daughter-in-law of Mr. Anil Jain, Managing DirectorRemuneration2000000Approved by the Audit Committee95600000Bajaj Healthcare Limited******Mrs. Khushi Jain******Daughter of Mr. Anil Champalal Jain, Managing Director & Sister of Mr. Pakshal Anil Jain, Whole-Time DirectorAny other transactionLegal & Professional Fees1200000Approved by the Audit Committee42000090000144000Bajaj Healthcare Limited******Mrs. Nihita Bajaj Kumar******Daughter of Mr. Sajankumar Bajaj, Chairman & Managing Director & Sister of Ms. Namrata Bajaj, Whole-Time DirectorAny other transactionLegal & Professional Fees2400000Approved by the Audit Committee1800000427000517000Bajaj Healthcare Limited******Taradevi Rameshwarlal Bajaj Charitable Trust******Charitable TrustAny other transactionCSR Expenses10000000Approved by the Audit Committee0033000Bajaj Healthcare Limited******Genrx Pharmaceuticals Private Limited******Body corporate directly/ indirectly owned by or significantly influenced by Director/s or their relativesAny other transactionOperating Expenses incurred by Bajaj on behalf of Genrx Pharmaceuticals100000000Approved by the Audit Committee4243000611900010362000The Company has acquired Genrx Pharmaceuticals Private Limited (in Liquidation) as a going concern through Sale Certificate dated 04.04.2025 & Possession Letter dated 05.04.2025. The status of Genrx Pharmaceuticals is in liquidation at ROC, hence there was no Board at the time of acquisition. Genrx Pharmaceuticals requires funding for their business/ operational purposes & to settle outstandings payments. On 03.06.2025, the Company filed an application before the National Company Law Tribunal (NCLT), Mumbai, seeking certain reliefs and concessions necessary for the effective takeover of the Genrx Pharmaceuticals Private Limited (in Liquidation), Corporate Debtor and to complete the acquisition as a going concern.Bajaj Healthcare Limited******Bajaj Sindhudurg Rice Mills Limited******Body corporate directly/ indirectly owned by or significantly influenced by Director/s or their relativesAny other transactionCapital Advance2000000Approved by the Audit Committee100000017460001852000Advance0No TenureUnsecuredCorporate Business Purposes51986000AuditedtrueWalker Chandiok Co & LLPtrue2026-05-08OthersAllotment of Equity Shares pursuant to the exercise of options for conversion of convertible warrants into equity shares2026-03-185271300002026-03-31trueCARE Ratings LimitedfalseNot ApplicableNo CommentsNo CommentsMr. Rohan ParekhChief Financial OfficerThane2026-05-08Repayment/ Prepayment of Secured/ Unsecured Loans from Bank/ NBFC in part or in fullNot Applicable1500000015000000150000000Investment of Capital ExpenditureNot Applicable350000035000003160000General Corporate PurposeNot Applicable2200000199700019840000